197 related articles for article (PubMed ID: 27422298)
1. Appropriateness Criteria for Active Surveillance of Prostate Cancer.
Cher ML; Dhir A; Auffenberg GB; Linsell S; Gao Y; Rosenberg B; Jafri SM; Klotz L; Miller DC; Ghani KR; Bernstein SJ; Montie JE; Lane BR;
J Urol; 2017 Jan; 197(1):67-74. PubMed ID: 27422298
[TBL] [Abstract][Full Text] [Related]
2. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
[TBL] [Abstract][Full Text] [Related]
5. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.
Weiner AB; Etzioni R; Eggener SE
Eur Urol; 2014 Oct; 66(4):611-2. PubMed ID: 24630416
[No Abstract] [Full Text] [Related]
6. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
7. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
8. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
9. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
10. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
11. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom.
Philippou Y; Raja H; Gnanapragasam VJ
BMC Urol; 2015 Jun; 15():52. PubMed ID: 26070313
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
14. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
15. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
16. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
[TBL] [Abstract][Full Text] [Related]
17. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
[TBL] [Abstract][Full Text] [Related]
18. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
Billis A; Guimaraes MS; Freitas LL; Meirelles L; Magna LA; Ferreira U
J Urol; 2008 Aug; 180(2):548-52; discussion 552-3. PubMed ID: 18550106
[TBL] [Abstract][Full Text] [Related]
19. Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
Ginsburg KB; Arcot R; Qi J; Linsell SM; Kaye DR; George AK; Cher ML;
J Urol; 2019 May; 201(5):923-928. PubMed ID: 30694939
[TBL] [Abstract][Full Text] [Related]
20. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
Musunuru HB; Yamamoto T; Klotz L; Ghanem G; Mamedov A; Sethukavalan P; Jethava V; Jain S; Zhang L; Vesprini D; Loblaw A
J Urol; 2016 Dec; 196(6):1651-1658. PubMed ID: 27569437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
